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abstract
The impact of cancer on patients’ lives can be measured using self-reported
questionnaires, known as Health-Related Quality of Life (HRQOL) measures. HRQOL
is deﬁned as a multi-dimensional construct covering disease and treatment-related
symptoms, physical, psychological, and social functioning.
The EORTC Quality of Life Group (QLG) was created in 1984 with the mission
to develop measures of HRQOL and to promote and coordinate clinical studies
concerning the quality of life of cancer patients. The EORTC Quality of Life
Department (QL Department) was founded in 1993 with the support of an EU grant
to provide administrative, practical and scientiﬁc support to co-operative groups
conducting clinical trials with HRQOL outcomes.
We are proud to report signiﬁcant scientiﬁc achievements that have made us
international leaders in HRQOL research and have led to real changes to cancer
patient treatments.
We developed a modular system for HRQOL measurement consisting of the EORTC
QLQ-C30, a core cancer quality of life questionnaire and supplementary questionnaire
modules. The EORTC-QLQ-C30 has been one of the most widely used cancer
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questionnaires in randomized trials in oncology as demonstrated by systematic
reviews. To date, the EORTC QLQ-C30 has been translated and linguistically validated
into more than 60 languages.
HRQOL outcome measures have been an integral part of EORTC clinical trials
for the last 30 years. We present examples of signiﬁcant, practice-changing clinical
trials evaluating HRQOL in several cancer sites, such as brain tumors, breast and
ovarian cancers, and malignant melanoma. In a series of systematic reviews, we
examined the quality of reporting HRQOL in international cancer clinical trials,
and the impact of the results on oncology practice that led to a recommendation
to improve CONSORT (Consolidated Standards of Reporting Trials) with regard to
reporting of HRQOL.
The QLG is an international leader in methodological research in the measurement
of HRQOL in oncology and pursues research in several key areas, such as cross-
cultural differences between populations in HRQOL assessment, Computer-Adaptive
Testing, electronic administration of EORTC QLQ-C30, and summary scores for EORTC
QLQ-C30.
In summary, the QLG and QL Department have been international leaders in the
ﬁeld. Our questionnaires have brought HRQOL assessment to the fore in many
international trials that have changed oncology practice and brought the patient’s
perspective into cancer research.
1. Introduction
Cancer and its treatment have a profound impact on
patients’ lives that can lead to difﬁculties in fulﬁlling
family roles, the ability to work, or the participation
in usual social activities. Even when successfully
treated, cancer may lead to longer-term physical and
psychological morbidity. The importance of measuring
not only the objective effects of cancer treatment, but
also its subjective impact on patients, has long been
recognized in clinical cancer research and oncology
practice. 1 Patient symptoms, functioning, and overall
well-being can be measured using carefully developed
and validated self-reported questionnaires, known as
HRQOL or Patient-Reported Outcome measures. HRQOL
is deﬁned as a multi-dimensional construct covering
at least several key dimensions, such as disease- and
treatment-related symptoms, physical, psychological
and social functioning. 2
HRQOL outcome measures have been an integral
part of EORTC (European Organisation for Research
and Treatment of Cancer) clinical trials for the last
30 years. The EORTC created the QLG in 1984 with
the mission to develop measures of patient-reported
outcomes in cancer, including HRQOL, and to promote
and coordinate clinical studies concerning the quality
of life of cancer patients. The QL Department based
at EORTC Headquarters was established in 1993 with
the support of an EU grant to provide administrative,
practical, and scientiﬁc support to all co-operative
groups conducting clinical trials that implement HRQOL
measures.
The QLG has a multi-disciplinary membership with
representatives from the medical and nursing profes-
sions as well as psychologists, statisticians, and social
scientists. Members come from seventeen European
countries, including Eastern Europe. Beyond Europe the
QLG has members fromTaiwan, Australia, Canada, Japan,
Israel, Egypt, Brazil, Hong Kong, Nepal, India, Central
and South America. The QLG thrives as an enthusiastic
dynamic group with a successful and active research
program that can make a signiﬁcant international
impact.
Over the years the HRQOL program has focused on
three major areas:
(1) Methodological research: aimed at developiong and
reﬁning questionnaires for assessing the HRQOL of
patients in oncology clinical trials, in other well-
designed research studies, and in clinical practice.
(2) Implementation in clinical trials: collaborating with
EORTC Research Groups in implementing HRQOL
studies within their clinical trial programs.
(3) Scientiﬁc research in patient-reported outcomes:
conducting research to better understand the effects
of cancer and its treatment on the HRQOL of diverse
populations of patients with cancer and to investigate
possible cross-cultural differences in these effects.
In each of those areas we are proud to report signiﬁcant
scientiﬁc achievements that have made us international
leaders in HRQOL research and, more importantly, have
led to real changes in the treatment of cancer patients.
© 2012 European Organisation for Research and Treatment of Cancer.
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2. Development and validation of a modular
system for HRQOL measurement: EORTC QLQ-C30,
a core cancer quality of life questionnaire and
supplementary questionnaire modules
In the 1990s the QLG introduced the concept of
modular HRQOL measurement in oncology based on a core
cancer questionnaire and cancer site-speciﬁc modules
covering speciﬁc symptoms, treatment side-effects, and
functional problems. 3 The QLG was the ﬁrst to publish
detailed guidelines on development of questionnaire
modules that have set the standard internationally and
have been widely used by researchers and clinicians
worldwide. 4 These have been regularly updated and are
now in their fourth edition (available online).
The most notable achievement of QLG is the de-
velopment and validation of the core EORTC HRQOL
questionnaire, known as EORTC QLQ-C30. The EORTC
QLQ-C30 was validated in multiple European countries
and published in 1993. 5 Evidence-based information
on clinically meaningful differences in the scores of
EORTC QLQ-C30 and recommendations for sample size
calculations using the EORTC QLQ-C30 sub-scales are
available. 6−9 The EORTC-QLQ-C30 has been one of the
most widely used cancer questionnaires in randomized
trials in oncology as demonstrated by systematic
reviews. 10−12 User agreements for the EORTC QLQ-C30
have been signed in more than 9,000 clinical trials or
academic studies worldwide. The EORTC QLQ-C30 rep-
resents probably the most widely known example of the
inﬂuence of the EORTC on international cancer research
(QLG Scientiﬁc Advisory Committee review report 2010).
In addition to the EORTC QLQ-C30, there is a
portfolio of supplementary questionnaire modules that
are cancer site-speciﬁc or symptom/quality of life
domain-speciﬁc, many of which are used in clinical trials
(see Table 1). This continues to be an active area of
research with ongoing development of questionnaires
for hematological malignancies, malignant melanoma,
doctor–patient communication, as well as updates to
existing modules to capture the effects of new treatment
modalities.
A truly unique feature of the EORTC questionnaires is
that attention is paid to cultural and linguistic issues
from the beginning of the developmental process. As the
globalization of clinical trials continues to increase, the
issues of the translation quality and cultural equivalence
of subjective measures are of paramount importance.
The QLG is an international leader in developing
guidelines for translations. 13 All of our questionnaires
are developed simultaneously in at least three European
languages, and all validated questionnaires are made
available in at least eight key European languages.
To date, the EORTC QLQ-C30 has been translated and
linguistically validated into more than 60 languages,
with more than 20 additional local adaptations and
Table 1 – Available EORTC questionnaire modules
Module Code
Validated EORTC Modules
Bone metastases BM22
Brain BN20
Breast BR23
Cervical CX24
Colorectal CR29
Colorectal liver metastases LMC21
Endometrial EN24
Gastric STO22
Head & neck H&N35
Information INFO25
Lung LC13
Multiple myeloma MY20
Oesophageal OES18
Oesophago-gastric OG25
Ovarian OV28
Palliative care PAL15
Prostate PR25
EORTC Modules in process of validationa
Carcinoid/neuroendocrine NET21
Cholangiocarcinoma and gallbladder BIL21
Chronic lymphocytic leukaemia CLL16
Elderly ELD15
Fatigue FA13
Hepatocellular carcinoma (primary liver cancer) HCC18
High dose chemotherapy HDC29
Muscle invasive bladder cancer BLM30
Ophthalmic OOPT30
Pancreatic PAN26
Chemotherapy-induced peripheral neuropathy CIPN20
Radiation proctitis PRT23
Spiritual wellbeing SWB36
Superﬁcial bladder cancer BLS24
Testicular TC26
a Developmental phase is completed, and large scale validation
in an international study is at various stages. Can be used in
clinical trials, but ﬁnal psychometric data is not available yet.
further translations in progress. Translations include
all major Western languages, and many African and
Asian languages. The translation work is a dynamic
and growing endeavor. The current list of existing
translations can be viewed in Table 2.
The QLG created the EORTC Item Bank, a searchable
database that contains all items (i.e., questions) from
validated modules and all their translations. It is a rich
resource for developing questionnaires, as it ensures
compatibility between different EORTC questionnaires
and their translations, avoids duplicating work, and
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Table 2 – Existing translations and adaptations of the EORTC QLQ-C30 questionnaire
Language Local adaptations Language Local adaptations
Afrikaans Lithuanian
Arabic Middle East, North Africa Malay Malaysia, Singapore
Bengali Malayalam
Bosnian Maltese
Bulgarian Marathi
Burmese Norwegian
Catalan Persian
Cebuano Polish
Chinese China, Hong Kong, Malaysia,
Singapore, Taiwan
Portuguese Portugal, Brazil
Croatian Punjabi
Czech Romanian
Danish Russian Russia, Belarus, Georgia
Dutch Serbian
Estonian Sinhala
Finnish Slovak
French Europe, Canada Slovenian
German Sotho
Greek Spanish Spain, Argentina, Chile, Colombia, Costa Rica, Guatemala, Mexico, Peru,
Puerto Rico, USA
Gujarati Swedish Sweden, Finland
Hebrew Tagalog India, Malaysia
Hindi Tamil
Hungarian Telugu
Icelandic Thai
Ilocano Turkish
Indonesian Ukrainian
Italian Urdu India, Pakistan
Japanese Vietnamese
Kannada Xhosa
Kiswahili Yoruba
Korean Zulu
Latvian
makes possible creation of ad hoc trial/research-speciﬁc
questionnaires using well-developed and validated
items. 14
The Group has developed ﬁve key publications support-
ing the application of its measurement system in clinical
trials and other research projects. These are regularly
updated and provided free of charge to all academic users
and can be downloaded from http://groups.eortc.be/qol:
(1) the EORTC QLQ-C30 scoring manual;
(2) guidelines for questionnaire module development;
(3) translation guidelines;
(4) guidelines for conducting clinical trial-based HRQOL
investigations;
(5) reference values for the EORTC QLQ-C30 for a wide
range of cancer diagnoses and for the general
population.
A platform for electronic administration of EORTC
QLQ-C30 is currently under development.
3. Examples of practice-changing EORTC trials
that included HRQOL
HRQOL is an integral part of most EORTC clinical trials
and has been systematically implemented over the last
15 years. Over 130 EORTC clinical trials have a HRQOL
element, typically as a secondary endpoint. However,
given that most regulatory bodies such as EMEA and
FDA now fully accept HRQOL as a valid endpoint and
issue label claims based on the impact of treatment on
patients, we believe the use of HRQOL in future EORTC
studies will only continue to grow.
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In Table 3 we present examples of signiﬁcant practice-
changing clinical trials with HRQOL sub-studies, all
designed and conducted by the QL Department and
run in collaboration with most of the EORTC Research
Groups. Just a couple of examples from Table 3
can demonstrate how HRQOL studies contributed to
changing clinical oncology practice.
In patients with glioblastoma, we studied the addition
of concomitant and adjuvant temozolomide to the stan-
dard treatment with radiotherapy and demonstrated that
temozolomide signiﬁcantly improved survival without
a negative effect on HRQOL. 17 This treatment is now
the standard of care in newly diagnosed patients with
glioblastoma.
Dose-intensive chemotherapy had generated much
interest in the treatment of patients with locally
advanced breast cancer as it might offer a survival
beneﬁt. We compared the effects of such an approach
with those of standard chemotherapy on HRQOL. 20
Patients assigned the intensiﬁed treatment had a
signiﬁcantly lower overall HRQOL score during the ﬁrst
three months, but scores returned to near baseline with
no difference between groups at 12 months and up to
2 years. This was the ﬁrst randomized trial to show
that dose-intensive treatment may lead to a temporary
reduction of HRQOL, followed by recovery, thus enabling
clinicians to give accurate information to their patients
and informing further research on intensive treatment
for patients with breast cancer.
These collaborative efforts have proved to be highly
successful and demonstrate the importance of multi-
disciplinary international collaboration. The EORTC, with
its strong network of clinical and methodological groups
and a keen interest in HRQOL, can provide important
clinical and patient-reported outcomes results that are
far reaching and have an impact on patient care on an
international scale.
The QL Department, on behalf of the EORTC Research
Groups, undertook the largest meta-analysis of HRQOL
data using the EORTC QLQ-C30. 24 The results provide the
most robust and compelling evidence amassed to date
that HRQOL scores can provide additional prognostic
information that can be used to assist in the prediction of
survival in cancer patients. The meta-analysis was based
on information provided at baseline by 7417 patients
who had completed the EORTC QLQ-C30 questionnaire.
The patients participated in 30 randomized controlled
trials conducted by the EORTC between 1986 and
2004, representing 11 different cancer sites. Variables
assessed in the meta-analysis included age, sex, WHO
performance status, distant metastases, cancer site, and
the 15 EORTC QLQ-C30 scales. The HRQOL parameters
physical functioning, pain, and appetite loss, provided
signiﬁcant prognostic information as did age, sex, and
distant metastases. These results strongly indicate that
in some cancer populations selected EORTC QLQ-C30
HRQOL scales provide valuable prognostic information
when combined with socio-demographic and clinical
information.
In a series of systematic reviews across many disease
sites, we examined the quality of reporting HRQOL in
international cancer clinical trials and the impact of the
results on oncology practice. This research undertaken
over a ﬁve-year period identiﬁed several hundred cancer
clinical trials in major disease areas (lung, breast,
prostate, brain, etc.) and made recommendations for the
need to improve CONSORT with regard to reporting of
HRQOL in clinical trials. 10−12,25−29
4. The QLG is an international leader in
methodological research in the measurement
of HRQOL in oncology
The QLG undertakes successful methodological research
in a number of key areas:
Cross-cultural differences between populations in HRQOL
assessment. 30−32 A large project database incorporating
125 datasets representing EORTC QLQ-C30 data from
over 30,000 individuals from 50 countries was used in
a speciﬁc statistical analysis based on Item Response
Theory (known as Differential Item Functioning). This
identiﬁed a number of item translations (pain, social
function) with evidence of differential performance
when compared with the original English version.
Results for the UK, North America, and Australia
were fairly similar but variations occurred for Eastern
European and Asian countries. Our results suggested
that the reasons for Asian countries were primarily
cultural rather than linguistic, in contrast with Europe
where response patterns followed linguistic lines. Some
of these effects were large enough to impact on the
results of clinical trials. The project demonstrated that
these statistical methods are useful for detection of
differences between translations that can be due to
either translation or cultural factors and thus can be
taken into consideration when interpreting international
studies. We used computer simulations to provide
recommendations about the sample size requirements
for future trials using differential item functioning
analyses of HRQOL instruments. 33
Computer-Adaptive Testing (CAT) Version of QLQ-C30.
This research aims to generate a dynamic, computer-
adaptive version of the EORTC QLQ-C30, based on
modern psychometric theory and techniques. The basic
idea of CAT is to tailor the questionnaire to the individual
respondent. Based on the responses to the preceding
items it is estimated which item should be asked next
to obtain maximal information on that individual’s
HRQOL (symptom level, functional status, etc.). Basing
the CAT on item response theory methods allows
one to directly compare scores between individuals
even though they may have answered different sets of
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Table 3 – Selected examples of EORTC trials with HRQOL sub-studies which informed clinical practice
Clinical trials Clinical ﬁndings Key HRQOL ﬁndings
HRQOL in brain tumors and brain radiotherapy
Prophylactic cranial irradiation (PCI) in
patients with extensive-disease
small-cell lung cancer (ED SCLC) 15
PCI leads to fewer
symptomatic brain
metastases and improved
survival
Short-term results up to three months showed a negative impact
of PCI on fatigue and hair loss. The impact of PCI on global health
status as well as on functioning scores was more limited. For
global health status, the observed mean difference was 8 points
on a scale 0 to 100 at six weeks (P=0.018) and three months
(P=0.055). PCI should be offered to all responding ED SCLC
patients. Patients should be informed of the potential adverse
effects from PCI.
Treatment with combined procarbazine,
CCNU (lomustine), and vincristine (PCV)
chemotherapy after radiotherapy (RT)
compared with RT alone in anaplastic
oligodendrogliomas EORTC 26951 trial 16
Adjuvant PCV improves
progression-free survival
PVC had a major impact on nausea/vomiting, loss of appetite,
and drowsiness during and shortly after treatment. There were
no long-term effects of PCV chemotherapy.
Radiotherapy alone versus radiotherapy
with concomitant and adjuvant
temozolomide for patients with
glioblastoma 17
Survival was higher for
patients assigned
combination treatment
compared with those
assigned standard
radiotherapy
At ﬁrst follow-up, groups differed only in social functioning,
favoring the radiotherapy-only group. Over subsequent
assessments, HRQOL was much the same between treatment
groups. The results indicate that temozolomide during and after
radiotherapy for patients with newly diagnosed glioblastoma
signiﬁcantly improved survival without a negative effect on
HRQOL and this treatment is now the standard of care.
Malignant melanoma
Adjuvant therapy with pegylated
interferon alfa-2b versus observation in
resected stage III melanoma 18
Treatment with
PEG-IFN-a-2b had a
signiﬁcant and sustained
effect on recurrence free
survival in this patient
population
A negative effect was observed on global HRQOL, two functioning
scales (social and role functioning) and three symptom scales
(appetite loss, fatigue, and dyspnea) at each post-baseline
assessment with the PEG-IFN-a-2b arm being the more impaired.
Adjuvant PEG-IFN-a-2b might not be the most appropriate
therapy for patients with high-risk melanoma, and appropriate
dose reduction and symptom management approaches can be
used to reduce the unwanted side effects of treatment.
Malignant mesothelioma
A phase III trial of ﬁrst-line treatment
with raltitrexed, a thymidine synthase
inhibitor, and cisplatin compared to
cisplatin alone in patients with
malignant pleural
mesothelioma (MPM). 19
The combination of
raltitrexed and cisplatin
improved overall survival
compared with cisplatin
alone
An extensive analysis of the HRQOL data did not show any
difference in on any of the scales, thus conﬁrming that a
combination chemotherapy of cisplatin and an antifolate is
superior to cisplatin alone in patients with MPM, without harmful
effect on HRQOL.
Breast cancer
Dose-intensive chemotherapy as
neo-adjuvant treatment of patients with
locally advanced breast cancer 20
No differences were found
in primary end point of
progression-free survival
Patients assigned the intensiﬁed treatment had a signiﬁcantly
lower overall HRQOL score during the ﬁrst three months than did
those assigned standard treatment (p=0.0015). However, scores
returned to near baseline, with no difference between groups, at
12 months and up to two years. We concluded that
dose-intensive treatment only has a temporary effect on HRQOL,
thus enabling more research on intensive treatment for patients
with breast cancer.
Patients with metastatic breast cancer
receiving the combination of
doxorubicin and paclitaxel (AT) or
doxorubicin and cyclophosphamide (AC)
as ﬁrst-line chemotherapy treatment 21
No differences in the
efﬁcacy study end points
were observed between
the two treatment arms.
Treatment-related toxicity
compromised
doxorubicin-delivered
dose-intensity in the
paclitaxel-based regimen
There were no statistically signiﬁcant differences in HRQOL
between the two treatment groups. In both groups, selected
aspects of HRQOL were impaired over time, with increased
fatigue, although some clinically signiﬁcant improvements in
emotional functioning were seen, as well as a reduction in pain
over time. Overall, global quality of life was maintained in both
treatment groups. This information is important when advising
women patients of the expected HRQOL consequences of
treatment regimens.
continued on next page
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Table 3 – (continued)
Clinical trials Clinical ﬁndings Key HRQOL ﬁndings
Head and neck cancer
Induction chemotherapy in unresectable
locoregionally advanced head and neck
cancer patients (docetaxel, cisplatin,
5-ﬂuorouracil [TPF] vs cisplatin
5-ﬂuorouracil [PF]) 22
An improved
progression-free and
overall survival with less
toxicity was found when
docetaxel (T) was added to
cisplatin and
5-ﬂuorouracil (PF) for
induction before
radiotherapy
There was a trend towards improved global HRQOL during the
treatment period. At six months after the end of radiotherapy,
global HRQOL was higher in the TPF arm than in the PF arm, with
bigger improvement in swallowing and coughing problems.
Induction chemotherapy with TPF before radiotherapy not only
improves survival and reduces toxicity compared with PF but also
seems to improve global HRQOL in a more sustainable manner.
Ovarian cancer
Phase III ovarian cancer trial of
neoadjuvant chemotherapy followed by
surgery compared with upfront
debulking surgery followed by
chemotherapy, EORTC 55971 trial 23
Survival was similar in
the upfront debulking
surgery arm compared to
the neoadjuvant
chemotherapy arm
No HRQOL differences were observed either. These results will
enable clinicians to provide evidence-based information to
patients to support decision making.
items. CAT has several advantages over traditional ﬁxed-
length questionnaires such as increased measurement
precision (smaller samples required), the questionnaire
can be adapted to the individual study (or even to the
respondent), avoidance of asking uninformative ques-
tions, and immediate calculation and presentation of
results. 34−36 The development of CAT requires more work
than traditional questionnaires. For each of the 14 HRQQL
domains in the EORTC QLQ-C30, an ‘item pool’ has to
be developed. For physical function (PF), for example, an
analysis of 975 previously used PF items identiﬁed in
the literature led to the development of 51 new items
that were tested with 1,176 patients from six countries.
Statistical evaluations reduced this to an item pool of
31 items which will be further tested. 34,35 Similar work is
being done for the other domains involving researchers
from 12 countries, and it is expected to collect data from
over 10,000 patients. 36 Scores obtained with the EORTC
CAT system are comparable with EORTC QLQ-C30 scores
thus maintaining the beneﬁts of using a questionnaire
already implemented and reported in many published
studies.
Electronic administration of EORTC QLQ-C30. Increas-
ingly many patient-reported outcomes measures are
administered in electronic formats including touch-
screen computers, web-based administration, mobile
telephones using screen data entry, and over the
phone using Interactive Voice Response (IVR). Electronic
administration reduces the burden of data management,
improves data quality, and allows real-time scoring and
immediate use of results in clinical practice. Many of
our Group members and other researchers worldwide
use EORTC QLQ-C30 in electronic formats, but until
recently the QLG has not formally supported a particular
electronic platform. A new project aims to provide
a web-based platform for electronic administration
of EORTC QLQ-C30 and the modules based on a
software solution called Computer-based Health Evalu-
ation System (CHES). 37 CHES is a PC-program for the
computerized assessment, calculation, and presentation
of psychosocial and medical data. Data is entered
by patients themselves via touch-screen or over the
Internet. The software application has a number of
features: graphical presentation of results, ﬂag system for
abnormal scores, clinical report generator, data export/
import module, interface to clinical information systems,
and study monitoring module. This electronic platform
will be explored in EORTC clinical trials.
Summary scores for EORTC QLQ-C30. Further research is
being undertaken to explore the possibility of generating
summary scores (so-called higher order factors) from
the EORTC QLQ-C30. In clinical trials, summary scores
could simplify certain analyses and minimize the chance
of Type I errors through multiple comparisons. In a
large existing sample of cancer patients (n=9000), we
empirically examined and compared the statistical ﬁt of
a number of alternative measurement models by means
of conﬁrmatory factor analysis. A model comprising of
Physical Health and Mental Health was best ﬁtting the
data. These results will lead to an algorithm for the
computation of summary scores for Physical Health and
Mental Health for the EORTC QLQ-C30.
5. Conclusion
The QLG and QL Department have been international
leaders in the development of patient-reported outcome
measures in oncology and their implementation in
oncology trials. Our most notable achievement is the
development and dissemination of the EORTC QLQ-C30
which, based on evidence from several systematic
reviews, is now arguably the most widely used can-
cer HRQOL instrument. We established internationally
accepted guidelines for questionnaire development.
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Our translation procedures set the highest standards
for questionnaire translation and are used worldwide.
These world-leading achievements have contributed
to bringing HRQOL assessment to the fore in many
international trials conducted by the EORTC and other
groups, have changed oncology practice, and enhanced
the patient perspective in clinical cancer research.
The Group now looks to the future with CAT and
CHES projects and developing ways to use information
technology to improve precision of HRQOL assessment
and accessibility to web-based interfaces that will
maximize the value of the data collected with EORTC
questionnaires.
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